Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies.

PubWeight™: 0.82‹?›

🔗 View Article (PMC 4053940)

Published in Vaccines (Basel) on March 01, 2014

Authors

Garnett Kelsoe1, Laurent Verkoczy2, Barton F Haynes3

Author Affiliations

1: Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA ; The Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
2: The Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA ; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
3: Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA ; The Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA ; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.

Articles cited by this

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91

Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14

The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04

Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem (2007) 6.92

Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell (2010) 5.49

Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature (1989) 5.48

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35

Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06

Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol (2005) 3.93

Pattern recognition receptors and control of adaptive immunity. Immunol Rev (2009) 3.91

Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med (2008) 3.87

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69

Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36

Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature (1991) 3.32

HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30

Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog (2011) 3.29

Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25

Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2009) 3.19

In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med (1992) 3.13

In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. III. The kinetics of V region mutation and selection in germinal center B cells. J Exp Med (1993) 3.13

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 3.04

Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68

Role of BCR affinity in T cell dependent antibody responses in vivo. Nat Immunol (2002) 2.63

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med (2012) 2.48

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med (2013) 2.31

Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science (2011) 2.17

Triggering TLR signaling in vaccination. Trends Immunol (2005) 2.09

Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J Exp Med (2002) 2.07

Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies (2005) 2.03

Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature (2012) 1.93

Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A (2009) 1.93

Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS (2003) 1.91

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78

Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med (2013) 1.68

B-cell self-tolerance in humans. Adv Immunol (2007) 1.65

Asymmetrical lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. J Exp Med (2006) 1.49

The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nat Rev Immunol (2005) 1.47

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One (2011) 1.41

In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nat Commun (2011) 1.41

Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J Immunol (2013) 1.39

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One (2012) 1.37

Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. J Immunol (2011) 1.25

Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One (2011) 1.15

Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J Immunol (2013) 1.14

Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Infect Immun (2002) 1.13

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol (2011) 1.13

Immunostimulatory activity of haptenated proteins. Proc Natl Acad Sci U S A (2009) 1.10

Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol (2013) 1.10

Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus (2002) 1.07

Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog (2013) 1.05

False-positive human immunodeficiency virus testing in patients with lupus erythematosus. Semin Arthritis Rheum (1993) 1.03

Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J Virol (2013) 1.02

Stromal cell independent B cell development in vitro: generation and recovery of autoreactive clones. J Immunol Methods (2010) 0.92

B cell tolerance--how to make it and how to break it. Curr Top Microbiol Immunol (2006) 0.88

Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. Arch Intern Med (2000) 0.86

Emerging studies of human HIV-specific antibody repertoires. Vaccine (2010) 0.81

Pathological roles of ganglioside mimicry in Guillain-Barré syndrome and related neuropathies. Adv Exp Med Biol (2011) 0.79